In a large clinical trial assessing Apretude, ViiV Healthcare’s recently approved injectable drug, as a form of HIV prevention, seven participants contracted the virus despite receiving their ...

Apretude is a medicine approved by the FDA in 2021 to reduce the risk of contracting HIV through sexual contact, also known as pre-exposure prophylaxis (PrEP). PrEP is used to prevent the transmission ...

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. This medicine is new or being used differently. Please report side ...

The federal Food and Drug Administration has approved Apretude (extended-release cabotegravir), the first long-acting injectable option for HIV prevention. The shots, which are administered by a ...

Given as few as six times per year and demonstrated superior efficacy to a daily oral PrEP option (FTC/TDF tablets) in reducing the risk of HIV acquisition Approved in the US for use in adults and ...

Prefer Newsweek on Google to see more of our trusted coverage when you search. A brand new drug might be more effective at preventing HIV than current methods. Many people take daily oral ...

(The Hill) – The Food and Drug Administration (FDA) has approved the first injectable treatment for HIV pre-exposure prophylaxis, providing another option to help individuals at-risk avoid sexually ...

An injectable drug to prevent HIV provides a substantial benefit, according to updated recommendations from the U.S. Preventive Services Task Force (USPSTF). The new recommendations for preexposure ...

When Parrish Brown reassures patients nervous about regular injections to reduce the risk of sexually transmitted HIV, he’s not only doing his job as a community health worker, he’s speaking from ...

Add Yahoo as a preferred source to see more of our stories on Google. In a large clinical trial assessing Apretude, ViiV Healthcare’s recently approved injectable drug, as a form of HIV prevention, ...